FMP
Inhibrx Biosciences, Inc.
INBX
NASDAQ
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.
14.1 USD
-0.05 (-0.355%)
Operating Data
Year
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
Revenue
9.09M
12.81M
7.13M
2.18M
1.8M
1.39M
1.08M
835.43k
646.82k
500.8k
Revenue %
-
40.86
-44.37
-69.43
-17.36
-22.58
-22.58
-22.58
-22.58
Ebitda
-42.6M
-67.44M
-76.56M
-125.82M
-206.69M
-1.39M
-1.08M
-835.43k
-646.82k
-500.8k
Ebitda %
-468.54
-526.57
-1.07k
-5.78k
-11.48k
-100
-100
-100
-100
Ebit
-45.12M
-69.84M
-79.25M
-127.04M
-207.88M
-1.39M
-1.08M
-835.43k
-646.82k
-500.8k
Ebit %
-496.23
-545.25
-1.11k
-5.83k
-11.55k
-100
-100
-100
-100
Depreciation
2.52M
2.39M
2.69M
1.23M
1.19M
575.61k
445.66k
345.05k
267.15k
206.84k
Depreciation %
27.69
18.68
37.73
56.24
66.17
41.3
41.3
41.3
41.3
EBIT (Operating profit)(Operating income)(Operating earning) = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) EBIT = (1*) (2*) -> operating process (leverage -> interest -> EBT -> tax -> net Income) EBITDA = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) + Depreciation + amortization EBITA = (1*) (2*) (3*) (4*) company's CURRENT operating profitability (i.e., how much profit it makes with its present assets and its operations on the products it produces and sells, as well as providing a proxy for cash flow) -> performance of a company (1*) discounting the effects of interest payments from different forms of financing (by ignoring interest payments), (2*) political jurisdictions (by ignoring tax), collections of assets (by ignoring depreciation of assets), and different takeover histories (by ignoring amortization often stemming from goodwill) (3*) collections of assets (by ignoring depreciation of assets) (4*) different takeover histories (by ignoring amortization often stemming from goodwill)
